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Two mutations in the cystatin B gene, a 3*
splice mutation and a stop codon mutation,
were previously found in patients with pro-
gressive myoclonus epilepsy of Unverricht-
Lundborg type [Pennacchio et al. (1996): Sci-
ence 271:1731–1734]. We present here a new
mutation 2404DTC: a 2-bp deletion within
the third exon of the cystatin B gene in an
Unverricht-Lundborg patient. This muta-
tion results in a frameshift and conse-
quently premature termination of protein
synthesis. Complete sequencing of the cod-
ing region and splice junctions of the cys-
tatin B gene showed that neither of the two
previously known mutations was present in
this patient. The level of cystatin B mRNA in
an immortalized cell line was found to be
decreased, as had been reported for other
Unverricht-Lundborg patients. The new
mutation further supports the argument
that defects in the cystatin B gene cause the
Unverricht-Lundborg form of progressive
myoclonus epilepsy. We describe a simple
PCR method which can detect the 2404DTC
deletion. This assay, together with previ-
ously described PCR assays for the other
two known mutations, should prove useful
in confirming clinically difficult diagnoses
of Unverricht-Lundborg disease. Am. J.
Med. Genet. 74:467–471, 1997.
© 1997 Wiley-Liss, Inc.
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INTRODUCTION
Progressive myoclonus epilepsy (PME) of the Unver-
richt-Lundborg type (U-L) is an inherited autosomal
recessive disorder (gene locus EPM1) characterized by
stimulus-sensitive myoclonus, tonic-clonic seizures,
and a progressive course beginning about age 6–15
years [Koskiniemi, 1974; Norio and Koskiniemi, 1979].
The disease is rare worldwide but more common in
Baltic countries and Finland [Eldridge et al., 1983],
affecting approximately 1 in 20,000 individuals in Fin-
land. In the Mediterranean it is known as Mediterra-
nean myoclonus (previously reported as a subgroup of
Ramsay Hunt syndrome [Roger et al., 1968; Malafosse
et al., 1992]). By genetic linkage analysis the putative
EPM1 gene was mapped to a 0.3-cM region on human
chromosome 21 [Lehesjoki et al., 1993]. Applying link-
age disequilibrium and haplotype analysis to the Finn-
ish population and searching for highly polymorphic
markers using a contiguous array of cosmid, BAC, and
P1 clones [Stone et al., 1996] narrowed the EPM1 locus
to a 175-kb segment [Virtaneva et al., 1996]. Recently,
the gene encoding cystatin B, a 98-amino acid cysteine
protease inhibitor, was localized to this region, and two
cystatin B point mutations in U-L patients were iden-
tified: a splice site mutation and a stop codon mutation
[Pennacchio et al., 1996]. These nucleotide substitu-
tions, 1925G → C and 2388C → T (GenBank accession
no. U46692), are presumed to be responsible for de-
creased levels of cystatin B messenger RNA in affected
individuals.
We describe here the complete sequencing of the cys-
tatin B coding region and splice junctions of an U-L
patient who has decreased cystatin B mRNA level but
lacks the previously characterized mutations. This pa-
tient was found to be heterozygous for a new mutation
2404DTC, a two-base pair (bp) deletion in the third
exon of the cystatin B gene. The mutation causes a
translational frameshift and subsequent protein trun-
cation after 74 amino acids.
We have developed a simple method for detecting the
new 2404DTC deletion. Enzymatic amplification of ge-
nomic DNA with a PCR primer having two mismatched
nucleotides and a nonmismatched primer yields a 204-
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bp product. The mismatched primer generates an XcmI
endonuclease site only when the 2404DTC mutation is
present, which can be detected by agarose gel electro-
phoresis and will be helpful for the development of a
molecular diagnostic assay for progressive myoclonus
epilepsy of Unverricht-Lundborg type.
MATERIALS AND METHODS
Subject
The patient studied here (EP6) is described in detail
as U-L patient 3 in a 5-hydroxy-L-tryptophan treat-
ment trial [Pranzatelli et al., 1995]. Clinical symptom-
atology and exclusion of other disorders are provided
there. After obtaining consent from the patient, geno-
mic DNA was isolated from peripheral blood using
standard techniques [Baas et al., 1984]. The research
reported here was approved by the University of Michi-
gan Institutional Review Board.
Northern Blot Analysis
Total RNA was isolated from lymphoblastoid cell
lines using TRIzol reagent (Gibco BRL, Grand Island,
NY) based on the method of Chomczynski and Sacchi
[1987]. Total RNA (34 mg) was denatured at 65°C for 10
min in 3-[N-morpholino]propanesulfonic acid
(MOPS)/formamide/formaldehyde buffer and loaded on
a 2% agarose/17.8% formaldehyde gel. After 15 hr of
electrophoresis, RNA was transferred to a Hybond-N
nylon membrane (Amersham, Arlington Heights, IL)
and fixed by baking for 2 hr at 80°C. The blot was
hybridized to a 0.8-kb 32P-labeled cystatin B PCR frag-
ment (primers F11 and R1; Table I) in ExpressHyb
hybridization solution (Clontech, Palo Alto, CA),
washed with 2 × SSC at room temperature for 40 min,
then with 0.1 × SSC at 50°C twice for 20 min, and
subjected to autoradiography. The membrane was
stripped by incubation in sterile H2O containing 0.5%
SDS during 10 min at 90–100°C and rehybridized to a
b-actin probe (Clontech, Palo Alto, CA) under similar
conditions.
DNA Sequencing of PCR Products
The coding region and intron-exon junctions of cys-
tatin B were PCR-amplified from genomic DNA with
the primers pF2, 51814R1, F11, and R1 [Pennacchio et
al., 1996] (Table I).
Amplification of the 58 part of the gene (primers pF2
and 51814R1) was carried out in 50 ml with 1 × PC2
buffer (Ab Peptides, Saint Louis, MO), 250 mM dNTPs,
0.2 mM primers, 5% DMSO, 10 units KlenTaq1 (Ab
Peptides), and 0.2 unit Pfu polymerase (Stratagene, La
Jolla, CA) at 94°C for 3 min followed by 30 cycles of
94°C for 1 min, 67°C for 1 min, and 4 min at 72°C, with
a final incubation for 10 min at 72°C.
Amplification of the 38 part of the gene (primers F11
and R1) was carried out using the same conditions,
except that 1 × PC2 was replaced by 1 × PEK buffer
[Ponce and Micol, 1992].
PCR products were subjected to automated sequenc-
ing in both directions with PCR primers and the inter-
nal primers pr194, pr585, pr38, and pr231 (Table I).
Diagnostic PCR Assay
A 204-bp DNA fragment containing the 2404DTC de-
letion was PCR-amplified from genomic DNA using
primers pr231 and pr133 (Table I). Reaction volume
was 25 ml with 1 × PEK buffer, 250 mM dNTPs, 0.2 mM
primers, 5 units KlenTaq1, and 0.1 unit Pfu polymer-
ase for 30 cycles of 94°C for 1 min, 67°C for 1 min, and
72°C for 2 min. PCR product (2.5 ml) was digested in a
volume of 15 ml with XcmI using the vendor’s condi-
TABLE I. Primers for PCR and Sequencing of Cystatin B Gene
Primer Orientation Sequence (58→38) Positiona
pF2 Forward CTCCGACTGCCCCTTCCCTATC 18–39
51814R1 Reverse GAGACACAGGGAAAGTTGCCATCT 1250–1227
F11 Forward CCACCGTACCCAGCTGGAACTGT 1729–1751
R1 Reverse CGGAGGATGACTTTGTCAGTCTTC 2536–2513
pr194 Forward GTCCCTTCTTGCGGGGCCACC 244–264
Pr585 Reverse CCCGAGCGGAGGGAGGCCTCT 635–615
pr38 Forward GAAGTTCCCTGTGTTTAAGGCCGTG 1958–1982
pr231 Forward TGTGAGGCATCCCCTGCACATG 2231–2252
pr44 Forward GCAGCAAGGTGACTTGGGATCAGAGG 2303–2328
pr133 Reverse GATAAGGTCAAGGGCTTGTTTTCCAGAGGG 2434–2405
aNumbering according to GenEMBL accession number U46692.
Fig. 1. Northern blot analysis of cystatin B total RNA in cell lines of one
U-L affected (lane 1) and three U-L unaffected (lanes 2–4) individuals. a:
Hybridization with 38 end of cystatin B gene. U-L patient shows lower level
of cystatin B expression than controls. b: Hybridization of the same blot
with human b-actin probe. Size of the RNA transcripts is indicated.
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tions (NEB, Beverly, MA). Digests were subjected to gel
electrophoresis in 2.5% agarose and photographed.
RESULTS AND DISCUSSION
We examined the level of cystatin B in the immor-
talized lymphoblastoid cells derived from U-L patient
EP6 and from 3 unaffected individuals. The 38 end of
the cystatin B gene and the b-actin control probe were
used to probe total RNA on a Northern blot (Fig. 1).
Hybridization with cystatin B revealed a 0.6-kb tran-
script corresponding to the fully processed transcript of
cystatin B [Ritonja et al., 1985]. The cystatin B mRNA
level of patient EP6 was markedly reduced compared to
the control samples (Fig. 1a), consistent with previous
observations that U-L patients have decreased cystatin
B mRNA levels [Pennacchio et al., 1996]. Probing for
b-actin confirmed that similar amounts of RNA were
present in all lanes (Fig. 1b). Reduced mRNA level for
cystatin B can have three causes: a defect in the pro-
moter region for the cystatin B gene, a mutation caus-
ing coding or splicing abnormalities which reduce the
amount or stability of mRNA, or a large deletion or
insertion, which is unlikely to be present in the region
of the cystatin B gene between nucleotides 1651–2822,
since no alterations were detected by Southern blot
analysis of BfaI genomic DNA digests hybridized to a
PCR fragment amplified with primers F11 and R1
(data not shown). The former two cases have been ob-
served: the stop and splice mutations were shown to
reduce the mRNA amount, but patients of Finnish ori-
gin and haplotype, in which no coding or splice muta-
tions were found, also showed reduced mRNA amounts
[Pennacchio et al., 1996] presumed to have regulatory
mutations, for instance in the promoter.
For cystatin B mutation analysis of patient EP6 we
screened the coding sequence of the gene and intron-
exon splice junctions using PCR combined with auto-
mated sequencing. For sequencing of PCR products,
previously published and newly synthesized internal
oligonucleotide primers were used (Table I). Sequence
comparison did not reveal any of the previously de-
scribed mutations in this patient: G-to-C transversion
at the last nucleotide of intron 1 and change CGA to
TGA, generating a translation stop codon at amino acid
position 68 [Pennacchio et al., 1996]. Sequence com-
parison did, however, identify a new mutation,
2404DTC, in the cystatin B gene of patient EP6: a de-
letion of two nucleotides in exon 3 (Fig. 2A). This mu-
tation, 2404DTC, causes a frameshift and a truncated
Fig. 2. A: Detection of a two-base pair (bp) deletion 2404DTC in the coding region of the cystatin B gene. Sections of chromatograms show the
nucleotide sequences of cystatin B (position 2414–2385, reverse) of a control (1) and of patient EP6 (2). Nucleotides designated by points in the sequence
of the unaffected person are deleted in Ep6. The heterozygous deletion causes the sequences of the two alleles to be staggered by 2 bp in the chromatogram.
B: Comparison of the predicted protein sequences of exon 3 in control (1) and mutant (2) alleles. Asterisks show positions of stop codons.
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74-amino acid protein by subsequent termination of
protein synthesis at the new codon TGA, 24 amino ac-
ids before the normal stop codon (Fig. 2B). No other
alterations were detected in the coding region and
splice junctions in the patient cystatin B gene of pa-
tient EP6.
Patient EP6 was found to be heterozygous for the
mutation 2404DTC: sequence analysis of the PCR prod-
ucts demonstrated a normal sequence in addition to a
2-bp-shorter product (Fig. 2A). The other allele had no
mutation in the gene regions analyzed, and thus may
represent a mutation in parts of the promoter that
have not yet been cloned.
Since Unverricht-Lundborg disease is usually diag-
nosed by clinical criteria in conjunction with exclusion
of similar disorders [Pranzatelli et al., 1995], molecular
diagnosis might be useful in the future. The earlier-
described 38 splice site mutation destroys the recogni-
tion site for the restriction enzyme BfaI and the stop
codon mutation creates a recognition site for BsaAI,
providing a simple test for screening affected individu-
als [Pennacchio et al., 1996]. To establish a simple
method for detecting the mutation 2404DTC in the cod-
ing region of suspected EPM1 patients, a PCR assay
was developed using primers surrounding the region of
deletion (primers 231 and 133, Table I). Since a com-
mercial enzyme for direct detection of the 2404DTC
mutation was not found, primers were designed in such
a way that a restriction site is created in PCR frag-
ments of affected individuals. Primer 133 contains two
internal mismatches: substitution of two nucleotides
on positions 2410A → T and 2411T →G for generation
of a restriction site for the endonuclease XcmI only in
mutant alleles (Fig. 3A). When an allele with the
2404DTC mutation is amplified, the product is cleav-
able with XcmI, in contrast to normal alleles. DNAs
from patient EP6 and 3 unaffected individuals were
assayed. All PCRs resulted in the expected 204-bp frag-
ment (data not shown). After digestion with XcmI, only
patient EP6 showed an additional band of 175 bp, in-
dicating heterozygosity for the 2404DTC mutation (Fig.
3B).
2404DTC is the third mutation in the cystatin B gene
identified to date. Haplotype analysis of specific popu-
lations [Lehesjoki et al., 1992; Malafosse et al., 1992;
Pennacchio et al., 1996] suggests that there will be only
a limited number of deleterious mutations in the ma-
jority of U-L patients. Therefore, it may be hoped that
molecular diagnosis by simple PCR may be possible in
the future.
Since submission of this paper, the mutation de-
scribed here has also been found by Lalioti et al. [1997]
Fig. 3. Screening assay for the 2404DTC mutation by PCR followed by restriction digest. A: Genomic DNA from unaffected (lanes 1–3) and affected
(lane 4) individuals was used for PCR amplification with primers 231 and 133, followed by restriction digest with XcmI. The PCR product of EP6 (lane
4) could be digested partially with XcmI (175-bp product) in contrast to control samples (lanes 1–3) in which the 204-bp product remained undigested.
The additional bands of apparent higher molecular weight in lane 4 are likely the result of heteroduplex formation between the two alleles. Size marker
(lane M): 1-kb DNA ladder. B: Creation of the XcmI restriction site with mismatched primer: (1) genomic sequence, (2) primer 133 sequence. Asterisks
show mismatched nucleotides in the template.
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and Lafreniere et al. [1997]. Neither study describes a
convenient PCR assay for this mutation. Lafreniere et
al. [1997] have shown an increased expansion in the 58
end of the gene detectable by Southern blot analysis in
the majority of patients, and we could now show that
the second mutation in this patient also has this ex-
pansion.
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